Award details

Identification of novel signal transducers in the mammalian unfolded protein response

Reference	BB/E006035/1
Principal Investigator / Supervisor	Dr Martin Schroeder
Co-Investigators / Co-Supervisors	Dr Josiah Simon, Professor Antony Slabas
Institution	Durham University
Department	Biological and Biomedical Sciences
Funding type	Research
Value (£)	669,221
Status	Completed
Type	Research Grant
Start date	01/06/2007
End date	31/07/2012
Duration	62 months

Abstract

Accumulation of unfolded proteins in the endoplasmic reticulum (ER) activates a signalling network called the unfolded protein response (UPR). The UPR regulates adaptive responses to ER stress, i.e. induction of ER resident chaperones, stimulation of ER associated degradation, ER expansion, and apoptosis. Engineering of the UPR promises to alleviate the bottleneck in recombinant protein production, folding and processing of the nascent polypeptide chain in the ER. The UPR is transduced through unconventional signalling events, i.e. non-spliceosomal splicing of mRNAs, preferentially translated mRNAs when general translation is inhibited, and activation of ER membrane proteins by proteolysis. The complete set of molecules activated by these signalling mechanisms has not been described. For many pathways only one higher eukaryotic substrate is known. We hypothesize that additional substrates for these pathways exist in mammalian cells. We propose to identify these substrates by using genomic technologies, i.e. transcript profiling and proteomics, coupled to exploitation of the unique biochemical features of these signalling pathways to identify novel components of the UPR. Murine NS0 cells, a cell line widely used for recombinant protein production, will be used in this study. Our characterisation of substrates for these pathways on a genomic scale will define the complete substrate spectra of these pathways. Therefore, our work will enable engineering of upstream components of these pathways with predictable outcomes on recombinant protein production and cell viability. The role of new factors identified through this work in activation of genes encoding ER resident molecular chaperones and UPR reporter constructs, cell viability and apoptosis will be studied by altering their expression level. In future work, we will test if alteration of expression level of these proteins is beneficial for heterologous protein production to secure IP rights for these processes.

Summary

Human proteins produced in other organisms, i.e. bacteria or mammalian cell cultures are called recombinant or heterologous proteins. These proteins have many applications in industry and medicine. They are safer to administer in the clinic than their native counterparts purified from i.e. animals. Single point mutations in a protein, i.e. isolated from pigs, that deviate from the human sequence, can have serious side effects when the protein is administered to humans. Further, their posttranslational modifications, i.e. their glycosylation pattern, are similar to those found in humans. Again, minor deviations in the glycosylation pattern between an animal and a human protein can seriously affected the performance of the protein in the human body. Finally, the risk of contamination of the protein with infectious agents is much easier controlled in production processes for recombinant proteins compared to isolation of the protein from animals. Production processes for recombinant proteins for use in the clinic rely on mammalian cell lines. Growth conditions and sterility requirements for these production processes make them expensive. Further, the number of recombinant proteins for which there is a demand on a multikilogram per year scale is rapidly growing, requiring the development of large scale (several cubic metres) production processes. The cost efficiency of a production process often determines if a recombinant protein makes it to the market and to the clinic. Several strategies have been devised to improve product yield and in turn the cost effectiveness of these production processes. To date, the rate-limiting step for production of recombinant proteins is folding into their native, active, and non-immunogenic conformation. Protein folding is assisted by helper proteins that shield a folding protein from its environment, called chaperones, and that catalyse a subset of protein folding reactions, called foldases. Recent basic research has identified signaltransduction pathways that sense the folding status of a protein, and that activate expression of these helper proteins to increase the efficiency of protein folding in response to this stress situation. Genetic engineering of these signalling pathways promises to alleviate the protein folding bottleneck in recombinant protein production. However, our current understanding of these signal transduction pathways is still limited. Based on our current knowledge the outcome of engineering of these pathways on recombinant protein production is unpredictable. To address this problem we propose to characterize these pathways on a genomic scale to define their complete substrate spectra by using recently developed genomic technologies to monitor the complete mRNA and protein population of a cell. In addition, we will exploit unique biochemical characteristics of these signalling pathways to focus our study on the pathways in question. In this way we will target three unique signal transduction mechanisms, non-spliceosomal splicing of mRNAs, preferentially translated mRNAs when translation of the majority of mRNAs is inhibited, and proteolytic activation of ER membrane proteins. We anticipate to identify new proteins involved in this response to protein unfolding. We will characterise the role of new genes involved in these signalling pathways identified in our study by characterising their role in chaperone and foldase expression, and survival of ER stress. Furthermore, through defining the complete substrate spectra of these pathways we will enable the engineering of these pathways with predictable outcomes on cell specific protein production and cell viability.

Committee	Closed Committee - Engineering & Biological Systems (EBS)
Research Topics	Industrial Biotechnology, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	Bioprocessing Research Industry Club (BRIC) [2006-2012]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search